Business

Abbott settles patent suit with Teva over antibiotic Omnicef

Posted July 18, 2010 11:00 pm

Abbott Laboratories said it settled a patent-infringement lawsuit filed against Teva Pharmaceutical Industries Ltd. over generic versions of the antibiotic Omnicef.

Terms are confidential, said Scott Stoffel, a spokesman for Livertyille Township-based Abbott. The companies filed documents July 15 in federal court in Chicago to dismiss the case. Denise Bradley, a spokeswoman for Teva, said the Petah Tikva, Israel-based company has no comment.

Omnicef sales in the U.S. plunged to $3 million in 2009 from $235 million in 2007 because of competition from generic copies, according to Abbott's annual report. The Abbott Park, Illinois-based company already settled a fight with Novartis AG's Sandoz unit over sales of generic Omnicef.

The drug is used to treat respiratory and skin infections.

Teva is the world's biggest generic-drug maker, and Sandoz is the second-biggest.

The case is Abbott Laboratories v. Teva Pharmaceuticals USA Inc., 07cv1721, U.S. District Court for the Northern District of Illinois (Chicago).

Article Comments

Article Categories
Business Communities Counties Lake County Libertyville North Chicago

Article Comments

Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the "flag" link in the lower-right corner of the comment box. To find our more, read our FAQ.